A phase 3 trial of Gilead Sciences’ remdesivir has demonstrated positive results in patients with moderate COVID-19 symptoms.
The study evaluated five-day and 10-day courses of the investigational antiviral plus the standard of care vs. standard of care alone in approximately 600 patients hospitalized with COVID-19.
Patients given remdesivir for five days were 65 percent more likely to have clinical improvement at day 11 compared with those in the standard of care group. The improvement in the patients given the 10-day treatment was not significantly better than in the five-day group.
Gilead released the results of a separate phase 3 trial last month, which showed that patients on a shorter dosing regimen saw clinical improvements similar to those on the 10-day treatment schedule (DID, April 30). — Jordan Williams